key: cord-0776710-83vr55og authors: Abeldano Zuniga, R. A.; Gonzalez Villoria, R. A. M.; Elizondo, M. V.; Nicolas Osorio, A. Y.; Coca, S. M. title: Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis date: 2021-01-22 journal: nan DOI: 10.1101/2021.01.16.21249956 sha: 9f942fc19daee0736668ffef59068c5565a2e6d3 doc_id: 776710 cord_uid: 83vr55og Given the variability of previously reported results, this systematic review aims to determine the clinical effectiveness of convalescent plasma employed in the treatment of hospitalized patients with diagnosis of COVID-19. We conducted a systematic review of controlled clinical trials assessing treatment with convalescent plasma for hospitalized patients with a diagnosis of SARS-CoV-2 infection. The outcomes were mortality, clinical improvement, and ventilation requirement. A total of 50 studies were retrieved from the databases. Four articles were finally included in the data extraction, qualitative and quantitative synthesis of results. The meta-analysis suggests that there is no benefit of convalescent plasma compared to standard care or placebo in the reduction of the overall mortality and in the ventilation requirement; but there could be a benefit for the clinical improvement in patients treated with plasma. We can conclude that the convalescent plasma transfusion cannot reduce the mortality or ventilation requirement in hospitalized patients diagnosed with SARS-CoV-2 infection. More controlled clinical trials conducted with methodologies that ensure a low risk of bias are still needed. Methods 1 A systematic review was conducted adhering to the PRISMA guidelines for 2 conducting systematic reviews (20) . The question in this review was: 3 What is the clinical effectiveness of convalescent plasma employed in the 4 treatment of hospitalized patients with diagnosis of COVID-19? To conduct the 5 review, the PICOS structure was followed according to these points: 6 • Patients: Adults hospitalized with a diagnosis of SARS-CoV-2 infection. 7 • Intervention: Treatment with convalescent plasma. 8 • Comparison: Placebo or standard care. 9 • Outcomes: Overall mortality, clinical improvement at seven days, clinical 10 improvement at 14 days, clinical improvement at 28 days, duration of ventilation 11 (days), duration of hospitalization (days), virological clearance, and severe 12 adverse events. 13 • Studies (type of): Clinical trials published in peer-reviewed journals. 14 The search was carried out in PubMed, Scopus, and Web of Science databases, 15 between November 20th, 2020, and January 9th, 2020. The references of the 16 selected articles were also reviewed for an integral reading to include additional 17 studies not indexed in these databases. The clinicaltrials.gov website was also 18 scanned to obtain potential published reports of registered trials. The search 19 strategies included the following keywords: convalescent plasma, COVID-19, 20 SARS-CoV2, and hospitalized. See the supplemental file for more details on the 21 search strategies. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 22, 2021. ; https://doi.org/10.1101/2021.01. 16.21249956 doi: medRxiv preprint Meta-analyses of inverse variance were conducted for three outcomes: clinical 1 improvement at day 7, ventilation requirement and overall mortality. Meta-analyses 2 were conducted with Revman v5.4 using pooled fixed effects odds ratios. The 3 significance and the magnitude of heterogeneity across studies were calculated 4 using the Q and I2 statistics. Odds ratios with 95% CIs were plotted for the 5 association between convalescent plasma compared with standard care or 6 placebo. Subgroup analyses were performed to examine differences according to 7 the population (All adults and older adults) in the treatment with convalescent 8 plasma for the ventilation requirement and the overall mortality in patients 9 diagnosed with SARS-Cov-2 infection. 10 The review protocol was registered on the PROSPERO platform 11 (CRD42020184436). 12 13 Following the described PICOS structure, this systematic review retrieved 50 15 studies from the databases. After the removal of 4 duplicates, 46 articles were read 16 in title and abstract. Forty-two were eliminated, resulting in 4 articles for full-text 17 reading. Four articles were finally included in the data extraction, qualitative and 18 quantitative synthesis of results (Figure 1 ). 19 The overall risk of bias in the reviewed articles was established at low-risk only in 20 one randomized, open-label clinical trial (17) . The remaining three studies were 21 established at high risk of bias due to issues in the randomization process 22 (16, 18, 19) . More details can be seen in the supplemental file. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 22, 2021. ; https://doi.org/10.1101/2021.01.16.21249956 doi: medRxiv preprint Patient samples ranged from 103 (the study with the fewest patients) to 464 (the 1 study with the most patients); three clinical trial included adult patients (16, 18, 19) , 2 while the fourth study was focused only in older adult patients (17) . The retrieved 3 results were: Mortality, clinical improvement at 7, 14, and 28 days (defined by 4 clinical scales), ventilation requirement, the mean duration of hospitalization (in 5 days), virological clearance (by laboratory tests), progression to severe disease 6 and severe adverse events (Table 1) . 7 The four studies reported using convalescent plasma at different dosage. Li (19) 8 reported a 4 to 13 mL/kg of recipient body weight dose, with possibility of receiving 9 a second dose (96% received a single dose transfusion). Agarwal (18) reported 2 10 doses of 200 ml, transfused 24 hours apart. Abolghasemi (16) reported 1 dose of 11 500 ml followed by a second dose of 500 ml If the patient did not show any 12 improvement after 24 hours. The study developed by Libster (17) in Argentina was 13 the only one that reported 250 ml of convalescent plasma with IgG titer greater 14 than 1:1000. Also, it is important to highlight that 2 studies used antiviral drugs in 15 both groups (16, 19) , one study used antiviral treatment in the control group (18), 16 and one study did not reported the use of drugs in any group (17) . 17 18 Outcomes assessed 19 The main outcome assessed by this systematic review was the mortality in 20 hospitalized patients diagnosed with SARS-CoV-2 infection. Two clinical trials 21 assessed the mortality of hospitalized patients at day 28 (18, 19) , and two studies 22 reported mortality at any time from randomization (16, 17) (Table 1) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 22, 2021. ; https://doi.org/10.1101/2021.01. 16.21249956 doi: medRxiv preprint The clinical improvement was reported by two studies. Li (19) has measured this 1 outcome at days 7,14 and 28 using the National Early Warning Score (NEWS) 2 2 (22), while Agarwal (18) has measured this outcome at day 7 as the proportion of 3 participants showing resolution of symptoms of fever, shortness of breath, or 4 fatigue. Abolghasemi (16) and Libster (17) did not assessed clinical improvement 5 ( Table 1) . 6 The progression to severe disease was assessed by Agarwal and Libster (17, 18) . 7 The definitions of this outcome differed in both clinical trials: PaO2/FiO2 ratio <100 8 mm Hg any time within 28 days of enrolment (18) ; and respiratory rate of 30 bpm 9 or more, SpO2 <93% at ambient air, or both (17) ( Table 1) . 10 The virological clearance was reported by two studies (18, 19) using different 11 criteria, and all studies reported adverse events identified in patients (16) (17) (18) (19) . The 12 study published by Li was the only one that assessed subgroups: all patients, 13 patients with severe disease, and patients with life-threatening disease (19) . Other Table 2 shows the main results from the four articles included in the qualitative 16 synthesis. The reduction in overall mortality is supported by Li(19) and 17 Abolghasemi (16), but Agarwal (18) and Libster (17) did not found statistically 18 significant differences. 19 Li and Agarwal conclusions state that the convalescent plasma transfusion did not 20 result in benefit for the intervention groups (18, 19) , while the studies published by 21 Abolghasemi and Libster stated that convalescent plasma was clinically effective in 22 COVID-19 patients (16, 17) . Since the conclusions reported by the included studies 23 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) differed, we decided to conduct the meta-analysis to obtain global estimations for 1 the outcomes of our interest. Meta-analysis 4 The result of two studies was integrated into the fixed-effects meta-analysis for 5 comparing convalescent plasma versus standard care in the clinical improvement 6 of patients diagnosed with SARS-CoV-2 infection (18, 19) . In this case, Three studies reporting ventilation requirement outcomes (16) (17) (18) were compared 10 to test the overall effect of convalescent plasma. The results of the random-effects Finally, the results of 3 studies (16, 18, 19) were meta-analyzed to establish CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 22, 2021. clinical trial. Considering only controlled clinical trials published in peer-reviewed 1 journals, 916 patients were included in hospitals from China, India, Iran, and 2 Argentina. 3 Regarding the overall quality of the studies, it must be noted that 3 out of 4 clinical 4 trial were considered at high risk of bias due to the lack of blinding. This is a 5 common characteristic of many clinical studies that started to run under emergency 6 conditions due to the persistent health crisis, with recurring waves in some 7 countries in Latin America, and other countries (23) . 8 There are four published systematic reviews on convalescent plasma that have 9 shown that this treatment could reduce the mortality (24-27), but did not included 10 only controlled trials and did not included the last study published by Libster (17) . 11 The current systematic review did not showed any benefit on the mortality 12 reduction, consistent with other three published systematic reviews (28) (29) (30) , while 13 other systematic reviews were focused on other infectious diseases such as Ebola, 14 influenza or SARS (31) (32) (33) , or other target populations (34) . 15 The use of convalescent plasma was associated with clinical improvement, which 16 is consistent with other previously published study (24, 27, 29) , however, Li (6) has 17 stated that plasma treatment has not been effective in critically ill patients, which 18 suggests that more stratified analysis are needed in primary studies. In addition, 19 the plasma transfusion has not been effective for avoiding the ventilation 20 requirement, as stated previously by Chai (29) . All this could suggest that the CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) hemorrhagic fever in Argentina has shown more effectiveness of convalescent 1 plasma in the first days of the clinical course (35) . Still, the optimal dosage and the 2 best time point for the convalescent plasma transfusion need to be determined in 3 well-designed clinical trials (36) . 4 Something that has been sufficiently proven before is that convalescent plasma In times of recurring waves of the COVID-19 pandemic, the analysis of potential 20 treatments proposed for hospitalized patients is still necessary since the 21 procurement and logistics of vaccines are still seen within a complex scenario for 22 many low-income countries. In many low-income countries, people are likely to 23 continue to be infected and to continue to die, where vaccination would occur two 24 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 22, 2021. ; https://doi.org/10.1101/2021.01.16.21249956 doi: medRxiv preprint to four quarters later partly due to logistical issues, as stated The World Bank (38) ; 1 so the search for a clinically effective treatment is still a major concern globally. 2 In the clinicaltrials.gov platform are currently registered dozens of clinical trials that 3 are assessing the treatment with plasma, so the addition of new evidence in the 4 coming months could change the direction of the analyzes in this review. infection. More controlled clinical trials conducted with methodologies that ensure a 10 low risk of bias are still needed. 11 12 All authors declare that there are no conflicts of interest. 13 There was no funding for this project. 14 All data are available upon request to the corresponding author. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 22, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 22, 2021. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma Kinetics of viral load and antibody response in relation to COVID-19 severity Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis Convalescent plasma transfusion therapy in severe COVID-19 patients-a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial Infusion of Convalescent Plasma is Associated with Clinical Improvement in Critically Ill Patients with COVID-19: A Pilot Study Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease Computerized monitoring of COVID-19 trials, studies and registries in ClinicalTrials.gov registry A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protoc COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Lifethreatening COVID-19 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19 Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma Therapeutic plasma exchange in adults with severe COVID-19 infection Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19) A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19 Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19? Minerva Med Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns Rekonvaleszentenplasma zur Behandlung von schwerem COVID-19: Rationale und Design einer randomisierten, offenen klinischen Studie von Rekonvaleszentenplasma verglichen mit bestmöglicher supportiver Behandlung (CAPSID-Studie). Transfusionsmedizin -Immunhämatologie · Hämotherapie · Transplantationsimmunologie · Zelltherapie Az első két sikeres, convalescens friss fagyasztott plazmával történő terápia hazai alkalmazása intenzív osztályon kezelt, kritikus állapotú, COVID-19-fertőzésben szenvedő betegekben Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working agai Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptorbinding domain IgG correlate with virus neutralization Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19 The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset Phase 2a, openlabel, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia